Quotes 5-day view Delayed Nasdaq
06/29/2022
06/30/2022
07/01/2022
07/05/2022
07/06/2022
Date
28.98(c)
29.43(c)
31.24(c)
31.68(c)
32.73(c)
Last
434 940
426 714
492 902
711 145
501 381
Volume
-1.09%
+1.55%
+6.15%
+1.41%
+3.31%
Change
Estimated financial data (e) (USD)
Sales 2022
104 M
-
-
Net income 2022
-327 M
-
-
Net cash position 2022
1 362 M
-
-
P/E ratio 2022
-12,2x
Yield 2022
-
Sales 2023
180 M
-
-
Net income 2023
-336 M
-
-
Net cash position 2023
1 222 M
-
-
P/E ratio 2023
-12,9x
Yield 2023
-
Capitalization
4 024 M
4 024 M
-
EV / Sales 2022
25,6x
EV / Sales 2023
15,6x
Nbr of Employees
380
Free-Float
79,5%
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator...
Ratings of Denali Therapeutics Inc.
All news about DENALI THERAPEUTICS INC.
News in other languages on DENALI THERAPEUTICS INC.
Analyst Recommendations on DENALI THERAPEUTICS INC.
Chart DENALI THERAPEUTICS INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends DENALI THERAPEUTICS INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
15
Last Close Price
32,73 $
Average target price
68,92 $
Spread / Average Target
111%
Please enable JavaScript in your browser's settings to use dynamic charts.